13 Liver Cancer Clinical Trials in New York, NY (2026)

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Recruiting Liver Cancer Studies in New York

NCT06427941Recruiting

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monother...

New York, NYPHASE1630 participantsBeOne Medicines

View Study Details

NCT06726161Recruiting

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC...

New York, NYPHASE1590 participantsRayzeBio, Inc.

View Study Details

NCT06914648Recruiting

The Dragon PLC Trial (DRAGON-PLC)

The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients w...

New York, NYNA358 participantsMaastricht University

View Study Details

NCT06084481Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is gi...

New York, NYPHASE1325 participantsAbbVie

View Study Details

NCT04906434Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

This is an open-label phase 1 study with an escalation part and an expansion part....

New York, NYPHASE1200 participantsAbbisko Therapeutics Co, Ltd

View Study Details

NCT04891289Recruiting

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in peopl...

New York, NYPHASE2164 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06600321Recruiting

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended d...

New York, NYPHASE1158 participantsAlnylam Pharmaceuticals

View Study Details

NCT06915753Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, includin...

New York, NYPHASE1125 participantsTyra Biosciences, Inc

View Study Details

NCT07164313Recruiting

A Study of ZW251 in Participants With Advanced Solid Tumors

The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma ...

New York, NYPHASE1100 participantsZymeworks BC Inc.

View Study Details

NCT07722741Recruiting

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically c...

New York, NYPHASE290 participantsGeneos Therapeutics

View Study Details

NCT06501625Recruiting

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in particip...

New York, NYPHASE152 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT05417932Recruiting

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma...

New York, NYPHASE146 participantsSCG Cell Therapy Pte. Ltd.

View Study Details

NCT07059494Recruiting

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

A single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y\^90 therapy with systemic atezolizumab and bevacizumab, in participants presenting with hep...

New York, NYPHASE440 participantsIcahn School of Medicine at Mount Sinai

View Study Details

About Liver Cancer Clinical Trials in New York

Liver cancer most commonly presents as hepatocellular carcinoma (HCC) and is often associated with chronic liver disease or hepatitis. It is one of the fastest-growing causes of cancer death. Treatment options include surgery, liver transplant, ablation, and systemic therapies.

There are currently 13 liver cancer clinical trials recruiting participants in New York, NY. These studies are seeking a combined 2,878 participants. Research is being sponsored by BeOne Medicines, RayzeBio, Inc., Maastricht University and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Liver Cancer Clinical Trials in New York — FAQ

Are there liver cancer clinical trials in New York?

Yes, there are 13 liver cancer clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What liver cancer treatments are being tested?

The 13 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for liver cancer.

Data updated October 3, 2026 from ClinicalTrials.gov